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Abstract: Synchronous or metachronous metastases develop in approximately
one third of all prostate cancer (PCa) patients. Main sites of metastasis
include lymph nodes, bone, lung and liver. Secondary peritoneal carcinoma-
tosis is very rare in PCa, with only a few published cases. 68Ga-PSMAPET–
based imaging is a promising tool for staging and restaging PCa.We report a
case of 68Ga-PSMA PET/MR–positive peritoneal metastasis as site of pri-
mary relapse after definitive PCa treatment in a 58-year-old man with a
prostate-specific antigen of 30 ng/mL at time of the study. Exploratory lap-
aroscopy and subsequent histopathologic examination confirmed nonascitic
peritoneal PCa carcinomatosis.
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FIGURE 1. 68Ga prostate-specific membrane antigen (PSMA) PET/MRI. A 58-year-old man previously treated with
robotic-assisted radical prostatectomy and lymph node sampling 11 years ago for a localized high-risk prostate cancer
(pT2c, pN0 [0/2], cM0, R0, Gleason 4 + 4 = 8, preoperative prostate-specific antigen [PSA] 40 ng/mL), who also received
salvage radiation therapy combined with 12 months of androgen deprivation for a para-anastomotic recurrence 18 months
after surgery, was referred for 68Ga-PSMA PET/MR for restaging because of previous repeated negative PET imaging (18F-choline
and 68Ga-bombesin) despite continuously rising PSA values (PSA at time of imaging 30 ng/mL,with an estimated PSA doubling
time of 11 months). A, Coronal and sagittal MIP of the 68Ga-PSMA PET/MR showed a single PSMA-positive hepatic lesion of
1.5 2.7 cmwith a SUVmax of 25.9. There was no evidence for local recurrence in the prostate bed on (B) axial T2-weighted
images or (C) axial-fused PET/MR. No positive lymph nodes, bone metastases, or any sign of ascites was detected. On the axial
(D) fat and (E) water weighted T1 3-dimensional dual-echo gradient-echo pulse DIXON-LAVA-Flex sequences, the lesion was
slightly hypointense (arrow), with (F) high PSMA accumulation on axial PET and (G) fused PET/MR.
FIGURE 2. Primovist liver MRI. Because an intrahepatic lesion
could not be ruled out on the PSMA PET/MR, the patient
underwent a dedicated liver MRI to further characterize the
PSMA-positive lesion. A, The PrimovistMRI revealed a single
peritoneal implant located on the falciform ligament without
contrast enhancement (yellow arrow, T1 FFE with fat
saturation, 20 minutes after contrast injection). B, On axial
diffusion-weighted images (b = 800), a clear diffusion
restriction was documented (arrow), further suggesting a
peritoneal metastasis. Exploratory laparoscopy confirmed
the lesion and revealed a disseminated peritoneal
carcinomatosis. The histopathologic analyses of the biopsy
specimens of the falciform ligament lesion and several other
peritoneal implants of 1 to 2 mm confirmed an infiltration
by an undifferentiated prostate adenocarcinoma Gleason
4 + 5 = 9. 68Ga-PSMA PET imaging offers promising
possibilities in restaging of biochemical recurrence, especially
at very low PSA values of less than 1 ng/mL.1–3 In addition,
an accurate detection of nodal and bonemetastases has been
demonstrated.4 Besides primary prostate cancer and its
metastases, 68Ga-PSMA uptake has been reported in
hepatocellular carcinoma and different othermalignant and
nonmalignant entities with high neovasculature.5–9 Peritoneal
carcinomatosis in metastatic prostate cancer is extremely
rare and has been described in only few single case
reports.10–13 68Ga-PSMA–based imaging might offer
improved detection rates for such occult visceral metastases.
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